Efficacy of integrative Traditional Chinese and Western medicine for the treatment of patients infected with 2019 novel coronavirus (COVID-19) A protocol for systematic review and meta analysis3800 Published on 2020-07-172022-10-30 Journal: Medicine [Category] COVID-19, SARS, [키워드] 2019 novel coronavirus adverse event Analysis bias risk Biomarker case sery Case-control CBM changes in China Chinese clinical recovery CNKI Cochrane Library collected Computed tomography conducted controlled trials Coronavirus disease 2019 COVID-19 data extraction database dosage drug duration of fever effective Efficacy eligibility criteria Ethical approval Ethics evaluate Evidence incidence include Infrastructure integrative Traditional Chinese and Western medicine journal Laboratory literature Meta-analysis Mild moderate Mortality outcome Patient patients with COVID-19 peer-reviewed performed primary outcome measure progression protocol Quality of life Randomized controlled trials searched secondary sensitivity analysis service severity SinoMed Symptoms System systematic review Therapeutic approach therapeutic option Traditional Treatment Vaccine VIP Web of Science [DOI] 10.1097/MD.0000000000020781 PMC 바로가기 [Article Type] 3800
The curative effects of shortwave diathermy on treating Novel coronavirus (COVID-19) pneumonia: A structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-07-032022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 1:1 Analysis approved baseline bleeding blinded Blinding block Blood China Chinese clinical Cognitive impairment Complete conducted contraindication control group Controlled clinical trial coronavirus COVID-19 curative dissemination Effect element evaluate evaluator exclusion criteria experimental group ground glass healthcare worker Hypothesis ICU include inclusion criteria Inflammation Intervention lactating women Lungs management manifestation mechanical ventilation multiple organ failure Mycoplasma novel nucleic acid test number objective outcome parallel group participant patchy pathogen Patient performed Pharyngeal swab Pneumonia positive primary outcome measure protocol randomised randomised controlled trial Randomized reached receiving Registered reported required Respiratory failure Sample size secondary outcome measure serum analysis Shock SIRS Standard status Study protocol Symptoms therapeutic effect therapy Tongji Hospital Treatment Trial Ultra short-wave diathermy underlying diseases vital sign website Wuhan [DOI] 10.1186/s13063-020-04534-5 PMC 바로가기 [Article Type] Letter
Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trialLetter Published on 2020-06-032022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 95% confidence interval Adjusted analysis Administered Admission age alcohol allocation concealment ALT/AST Analysis Arm arrhythmia assigned Beta block-randomization Blood calculated Care center clinical Clinical improvement clinical trial conducted confirmed case control group cough COVID-19 COVID-19 confirmed patient COVID-19 in patient COVID-2019 Cox proportional-hazards model death discharge disease dissemination drug Duration education Effectiveness element eligibility enrolled excluded exclusion criteria fatigue follow-up time hazard headache Health hospital hospital discharge Hospitalization Hydroxychloroquine + Lopinavir/Ritonavir improvement include Interaction Interferon beta-1a Interferon-β 1a Interferon-β 1b intervals intervention group investigator Kaletra Kaplan–Meier laboratory result lactating women Last limit log-rank test Loghman Hakim Hospital Lopinavir Lopinavir/ritonavir masking mechanical ventilation Medical Science Medical Sciences moderate Mortality myalgia nasal NCT04343768 number objective open label Open-label Other outcome oxygen saturation package parallel group participant Patient performed positive pregnant Primary outcome primary outcome measure problem professional protocol pulse-oximetry R software R version 3.6.1 randomization randomization sequence Randomized Randomized controlled trial Randomly reached receive Recigen recruitment refusal regimen Registered Research respiratory rate RT-PCR test Sample SARS-CoV-2 sealed secondary secondary outcome seven-category ordinal scale single center single dose SpO2 sputum production standard care status Study protocol Symptom temperature tested the patient therapeutic three groups time treat treated treatment groups Trial university version 3.6.1 website World Health Organization Ziferon [DOI] 10.1186/s13063-020-04382-3 PMC 바로가기 [Article Type] Letter
TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral TherapyTAILoR(인간 면역결핍 바이러스[HIV]의 TelmisArtan 및 InsuLin 내성): 복합 항레트로바이러스 요법을 받는 HIV 양성 환자의 인슐린 내성 감소를 위한 Telmisartan의 적응형 설계, 용량 범위 IIb상 무작위 시험Articles and Commentaries Published on 2020-05-152022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] adaptive Analysis antiretroviral drugs Antiretroviral therapy Antiretrovirals ARMS cardiovascular disease check clinical Combination conducted Controlled trial demonstrated Efficacy evaluated fat had no HIV HIV infection homeostasis Human Human immunodeficiency virus identify IIb immunodeficiency virus improvement Improvements index individual Infection insulin insulin resistance Insulin sensitivity interim analysis Intervention investigated ISRCTN liver longitudinal longitudinal analysis measure metabolic abnormalities Metabolic abnormality metabolic disease morbidity and mortality multicenter no difference no differences no significant effect once daily Open-label participant Patient phase plasma Primary outcome primary outcome measure Randomized receiving recruited reduce reduction in Registration resistance Result risk secondary outcome measures significant effect Stage stage II telmisartan Trial with HIV [DOI] 10.1093/cid/ciz589 PMC 바로가기 [Article Type] Articles and Commentaries